An update on antidepressant use and suicidality in pediatric depression

Clara Adegbite-Adeniyi, Brittany Gron, Brieana M. Rowles, Christine A. Demeter, Robert L Findling

Research output: Contribution to journalArticle

Abstract

Introduction: In 2003, public health advisories in North America and Europe regarding suicidality associated with selective serotonin reuptake inhibitors (SSRIs) led to the addition of black box warnings to antidepressant package inserts in 2004. Subsequently, a series of events appeared to result from these regulatory actions. Areas covered: This review provides an overview of the temporal associations of regulatory agencies' actions in North America and Europe with rates of depression diagnoses, pediatric antidepressant prescription rates, follow-up visits to physicians prescribing antidepressants, and rates of completed suicide and suicidal ideation in children and adolescents. In addition, evidence-based predictors of suicidal behavior and suicide risk, as provided by large, multisite studies of depressed children and adolescents, are outlined. Finally, this review considers key advancements in the study of young patients at risk for suicide and describes innovations in current research methodology, to more accurately identify suicidality and the relationship to antidepressant use within this vulnerable patient population. Expert opinion: Evaluating the role of antidepressants in those youths who do not respond to evidence-based psychotherapeutic interventions may be a useful future research direction. Until more data are available, however, closely monitored antidepressant treatment in combination with CBT may provide the most benefit.

Original languageEnglish (US)
Pages (from-to)2119-2130
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume13
Issue number15
DOIs
StatePublished - Oct 2012
Externally publishedYes

Fingerprint

Antidepressive Agents
Depression
Pediatrics
Suicide
North America
Drug Labeling
Product Labeling
Suicidal Ideation
Serotonin Uptake Inhibitors
Expert Testimony
Vulnerable Populations
Prescriptions
Research Design
Public Health
Physicians

Keywords

  • Antidepressants
  • Children and adolescents
  • Depressive disorders
  • Suicidality

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

An update on antidepressant use and suicidality in pediatric depression. / Adegbite-Adeniyi, Clara; Gron, Brittany; Rowles, Brieana M.; Demeter, Christine A.; Findling, Robert L.

In: Expert Opinion on Pharmacotherapy, Vol. 13, No. 15, 10.2012, p. 2119-2130.

Research output: Contribution to journalArticle

Adegbite-Adeniyi, Clara ; Gron, Brittany ; Rowles, Brieana M. ; Demeter, Christine A. ; Findling, Robert L. / An update on antidepressant use and suicidality in pediatric depression. In: Expert Opinion on Pharmacotherapy. 2012 ; Vol. 13, No. 15. pp. 2119-2130.
@article{b6bba5aa4d8c442194a094a60427665d,
title = "An update on antidepressant use and suicidality in pediatric depression",
abstract = "Introduction: In 2003, public health advisories in North America and Europe regarding suicidality associated with selective serotonin reuptake inhibitors (SSRIs) led to the addition of black box warnings to antidepressant package inserts in 2004. Subsequently, a series of events appeared to result from these regulatory actions. Areas covered: This review provides an overview of the temporal associations of regulatory agencies' actions in North America and Europe with rates of depression diagnoses, pediatric antidepressant prescription rates, follow-up visits to physicians prescribing antidepressants, and rates of completed suicide and suicidal ideation in children and adolescents. In addition, evidence-based predictors of suicidal behavior and suicide risk, as provided by large, multisite studies of depressed children and adolescents, are outlined. Finally, this review considers key advancements in the study of young patients at risk for suicide and describes innovations in current research methodology, to more accurately identify suicidality and the relationship to antidepressant use within this vulnerable patient population. Expert opinion: Evaluating the role of antidepressants in those youths who do not respond to evidence-based psychotherapeutic interventions may be a useful future research direction. Until more data are available, however, closely monitored antidepressant treatment in combination with CBT may provide the most benefit.",
keywords = "Antidepressants, Children and adolescents, Depressive disorders, Suicidality",
author = "Clara Adegbite-Adeniyi and Brittany Gron and Rowles, {Brieana M.} and Demeter, {Christine A.} and Findling, {Robert L}",
year = "2012",
month = "10",
doi = "10.1517/14656566.2012.726613",
language = "English (US)",
volume = "13",
pages = "2119--2130",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "15",

}

TY - JOUR

T1 - An update on antidepressant use and suicidality in pediatric depression

AU - Adegbite-Adeniyi, Clara

AU - Gron, Brittany

AU - Rowles, Brieana M.

AU - Demeter, Christine A.

AU - Findling, Robert L

PY - 2012/10

Y1 - 2012/10

N2 - Introduction: In 2003, public health advisories in North America and Europe regarding suicidality associated with selective serotonin reuptake inhibitors (SSRIs) led to the addition of black box warnings to antidepressant package inserts in 2004. Subsequently, a series of events appeared to result from these regulatory actions. Areas covered: This review provides an overview of the temporal associations of regulatory agencies' actions in North America and Europe with rates of depression diagnoses, pediatric antidepressant prescription rates, follow-up visits to physicians prescribing antidepressants, and rates of completed suicide and suicidal ideation in children and adolescents. In addition, evidence-based predictors of suicidal behavior and suicide risk, as provided by large, multisite studies of depressed children and adolescents, are outlined. Finally, this review considers key advancements in the study of young patients at risk for suicide and describes innovations in current research methodology, to more accurately identify suicidality and the relationship to antidepressant use within this vulnerable patient population. Expert opinion: Evaluating the role of antidepressants in those youths who do not respond to evidence-based psychotherapeutic interventions may be a useful future research direction. Until more data are available, however, closely monitored antidepressant treatment in combination with CBT may provide the most benefit.

AB - Introduction: In 2003, public health advisories in North America and Europe regarding suicidality associated with selective serotonin reuptake inhibitors (SSRIs) led to the addition of black box warnings to antidepressant package inserts in 2004. Subsequently, a series of events appeared to result from these regulatory actions. Areas covered: This review provides an overview of the temporal associations of regulatory agencies' actions in North America and Europe with rates of depression diagnoses, pediatric antidepressant prescription rates, follow-up visits to physicians prescribing antidepressants, and rates of completed suicide and suicidal ideation in children and adolescents. In addition, evidence-based predictors of suicidal behavior and suicide risk, as provided by large, multisite studies of depressed children and adolescents, are outlined. Finally, this review considers key advancements in the study of young patients at risk for suicide and describes innovations in current research methodology, to more accurately identify suicidality and the relationship to antidepressant use within this vulnerable patient population. Expert opinion: Evaluating the role of antidepressants in those youths who do not respond to evidence-based psychotherapeutic interventions may be a useful future research direction. Until more data are available, however, closely monitored antidepressant treatment in combination with CBT may provide the most benefit.

KW - Antidepressants

KW - Children and adolescents

KW - Depressive disorders

KW - Suicidality

UR - http://www.scopus.com/inward/record.url?scp=84866495056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866495056&partnerID=8YFLogxK

U2 - 10.1517/14656566.2012.726613

DO - 10.1517/14656566.2012.726613

M3 - Article

VL - 13

SP - 2119

EP - 2130

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 15

ER -